corilagin protects non-alcoholic fatty liver disease in mice induced by high fat and high sugar diet via regulating AMPK-autophagy signaling北大核心CSCD

Aim To explore the effects of corilagin on non-alcoholic fatty liver disease induced by high-fat and high-sugar diet in mice via regulating AMPK-autophagy signaling. Methods Healthy 8-week-old male C57BL/6J mice were randomly divided into control group, model group and corilagin group. The mice of model group and corilagin group were fed with a high-fat and high-sugar diet for four weeks at the age of eight weeks. The corilagin group mice were also intraperitoneally injected with corilagin (20 mg • k g - 1 ), which was given once every 2 days for 4 weeks. The mice of the control group and the model group were given equal dose of normal saline. After modeling and administration, the mice were sacrificed and the liver weight recorded. The liver pathological changes of each group mice were assessed by HE staining, oil red O staining and Masson staining. The biochemical indexes in serum and liver tissue were detected by the ELISA kit. The p-AMPK and autophagy levels were detected by Western blot. Results The results showed that compared to control group, the liver weight of the model group increased, the AST and ALT levels in serum also significantly increased, there were a large number of fat vacuoles and severe lipid deposition and mild collagen fibrosis in liver, while the liver weight and TG level in liver significantly decreased, and the liver pathological changes were significantly improved after treated with corilagin. Western blot results showed the levels of autophagy related proteins such as Atg7 and Atg5 significantly decreased in the model group, and the p-AMPK level also significantly decreased. When treated with corilagin, p-AMPK and the autophagy levels were up-regulated. Conclusion corilagin can protect non-alcoholic fatty liver disease in mice induced by high fat and high sugar diet. The mechanism may involve increasing p-AMPK level and enhancing autophagy level in liver. © 2023 Publication Centre of Anhui Medical University. All rights reserved.     

银杏叶提取物注射液联合神经节苷脂治疗缺血性脑血管病的疗效观察研究

目的:观察银杏叶提取物注射液联合神经节苷脂治疗缺血性脑血管病的临床疗效。方法:根据患者的情况选择治疗方法,对不能溶栓的患者采取抗凝治疗,其他患者3 h内均采用溶栓治疗,在此基础上,A组患者中采用神经节苷脂静脉滴注,B组患者则在A组的基础上联合银杏叶提取物注射液,对比两组患者的总临床疗效率、血流动力学指标、治疗后的总不良反应率以及治疗前后的美国国立卫生院卒中量表(National Institutes of Health Stroke Scale,NIHSS)评分。结果:B组患者总临床疗效率高于A组,B组患者的全血低切粘度、全血高切粘度、纤维蛋白原、红细胞比容均低于A组,B组患者的总不良反应率低于A组,B组患者的NIHSS评分在降低幅度上明显优于A组,差异符合统计学意义(P<0.05)。结论:银杏叶提取物注射液联合神经节苷脂治疗缺血性脑血管病临床疗效更佳,能有效改善患者的脑循环,促进神经血管的恢复情况,应用前景广阔。